title: Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
abstract: Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia.
authors.affiliation: Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany.
authors.forename: Haefaa
authors.initials: H
authors.lastname: Alchalby
authors.affiliation: Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany.
authors.forename: Tatjana
authors.initials: T
authors.lastname: Zabelina
authors.affiliation: Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Stübig
authors.affiliation: EBMT Data Office, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Anja
authors.initials: A
authors.lastname: van Biezen
authors.affiliation: Medizinische Klinik und Poliklinik I, University Hospital Dresden, Dresden, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.affiliation: Department of Hematology, Ospedale Civile, Pescara, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Di Bartolomeo
authors.affiliation: Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
authors.forename: Dietrich
authors.initials: D
authors.lastname: Beelen
authors.affiliation: Hématologie Clinique, Hopital A. Michallon, Grenoble, France.
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Cahn
authors.affiliation: Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Dreger
authors.affiliation: Department of Hematology, Antwerp University Hospital, Antwerp, Belgium.
authors.forename: William
authors.initials: W
authors.lastname: Schroyens
authors.affiliation: Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: Theo
authors.initials: T
authors.lastname: de Witte
authors.affiliation: Servicio de Hematologia, Hospital de Navarra, Pamplona, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarria
authors.affiliation: Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany. Electronic address: nkroeger@uke.uni-hamburg.d.
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005060:Europe; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications*; D009364:Neoplasm Recurrence, Local; D055728:Primary Myelofibrosis / Q000628:therapy*; D012074:Remission Induction; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects*
keywords: Allogeneic stem cell transplantation; Blast phase; Complete remission; Myelofibrosis; Transformed AML